BETHANIA MPCH INFLUENZA “A” OUTBREAK- UPDATE JANUARY 12, 2024


Update: January 12, 2024

Dear Residents and Families:

As of today, we have one confirmed COVID 19 positive resident on 600 wing who remains in isolation. Currently, there are 7 Residents who have had confirmed Influenza A with 2 pending tests. In following Outbreak protocol, therefore all residents on Center and South units have been started on prophylaxis Tamiflu medication unless they or their families have refused this treatment. Residents that are positive for Influenza A or are presenting with Influenza Like Illness symptoms and awaiting swab results are receiving treatment dosage of Tamiflu.

Residents who have tested positive or are awaiting lab results are required to remain in their rooms on the Wings including at mealtimes. All other Residents are not isolated to their Wings any longer and can take meals in their usual places. Recreation and Spiritual programming will continue and residents on isolation will receive one on one programing. Nursing Staff are carefully monitoring all Residents to detect any signs and symptoms of influenza infection or other viruses.

Visitation can continue for all Residents however those visiting Residents who have tested positive or are on additional precautions, should consult with Nursing staff about PPE and other infection prevention practices.
We encourage all family and other visitors still wear a mask during their entire visit, sanitize their hands before and after visiting and to not visit if feeling ill. This latest outbreak reinforces the importance of staying up to date with vaccinations.

Again, our profound thanks to all staff at Bethania for their outstanding care, infection control practices and support during this outbreak.

Please keep our Residents and Staff in your thoughts and prayers.

Gary J. Ledoux
CEO, The Bethania Group

Doris Furtado RN, GNC (C)
Director of Care

_______________________________________________
INFORMATION ABOUT Tamiflu™ (also known as Oseltamivir)
1. What is Tamiflu™
Tamiflu™ is a prescription medication which has been shown to be about 80% effective in preventing influenza. It is the only medication known which will prevent influenza outbreaks caused by influenza B or influenza A resistant to another drug used for prevention, amantadine.
It has also been shown to be effective in reducing the length of symptoms and complications following infection with influenza. It is a capsule taken by mouth.
2. What are the side effects of Tamiflu™?
Tamiflu™ does not usually cause many side effects. The most common side- effects are nausea and vomiting and diarrhea in 4 – 6% of people. These do not last long and usually occur with the first dose. Taking Tamiflu™ with food may reduce these side effects. More serious reactions have been reported but the drug has not been proven to be the cause.
3. Does Tamiflu™ interact with other medications?
Existing information does not indicate that there are any clinically important interactions with other medications.
4. How long will Tamiflu™ be given?
Tamiflu™ is usually given for about 10 days, the average time that an influenza outbreak lasts.
5. What happens if a person develops influenza when taking Tamiflu™?
Since Tamiflu™ can reduce the length of symptoms and complications, it will be given at a higher treatment dose for 5 days and then stopped.
6. Do residents/patients have to take Tamiflu™?
No. If a decision is made not to receive Tamiflu™, no changes will be made to any care or treatments already in place.
7. Is there a cost?
No, in this situation only, the medication is provided at no charge.
8. Who should not take Tamiflu™?
Anyone who has had a severe allergic reaction to Tamiflu™. Persons with severe kidney disease (check with the doctor prescribing Tamiflu™). Persons who are pregnant may become pregnant or are breast-feeding.